Tumor Immunology and Therapies
The Tumor Immunology and Therapies group in the C.S. Mott Center for Human Growth and Development is composed of basic science researchers and clinician scientist in the field of ovarian cancer research. As majority of ovarian cancer patients succumb to the disease during the recurrent stage, the group's objective is anchored upon the better understanding and management of recurrent ovarian cancer. Collectively, the group focuses on: drug discovery, development of novel immunotherapies, drug delivery platforms, markers for early detection, and development of relevant in vitro and in vivo models.
Radhika Gogoi, MD, PhD
Alvero AB, Hanlon D, Pitruzzello M, Filler R, Robinson E, Sobolev O, Tedja R, Ventura A, Bosenberg M, Edelson R, Mor G. Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer. Oncoimmunology, 2020.
Li J, Alvero AB, Nuti S, Tedja R, Roberts CM, Pitruzzello M, Li Y, Xiao Q, Zhang S, Gan Y, Wu X, Mor G, Yin G. CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. Oncogene, 2020.
Dasari, VR, Carey DJ, Gogoi R. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells. BMC Cancer, 2020.